Lobg G 1 Tablet contains a combination of Lobeglitazone Sulfate (0.5 mg) and Glimepiride (1 mg), formulated for the management of type 2 diabetes mellitus. Lobeglitazone, a thiazolidinedione class agent, improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), thereby enhancing peripheral glucose uptake and reducing hepatic glucose production. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, contributing to improved glycemic control. This dual mechanism addresses both insulin resistance and insulin deficiency, making Lobg G 1 effective in achieving target blood glucose levels when diet and exercise alone are insufficient. The combination is indicated for adult patients with type 2 diabetes who require additional glycemic control. Administration should be individualized based on patient response and tolerability, with careful monitoring of blood glucose to minimize the risk of hypoglycemia, particularly due to glimepiride. Caution is advised in patients with hepatic or renal impairment, heart failure, or a history of hypersensitivity to thiazolidinediones or sulfonylureas. Regular assessment of glycemic parameters and clinical status is essential to optimize therapy and reduce the risk of adverse effects. Lobg G 1 Tablet should be used as part of a comprehensive diabetes management plan including lifestyle modifications.